New Enterprise Associates 17, L.P. 3
3 · SpyGlass Pharma, Inc. · Filed Feb 5, 2026
Insider Transaction Report
Form 3
New Enterprise Associates 17, L.P.
10% Owner
Holdings
Series B Preferred Stock
[F1][F2]→ Common Stock (1,619,240 underlying)Series C-1 Preferred Stock
[F1][F2]→ Common Stock (1,370,168 underlying)Series C-2 Preferred Stock
[F1][F2]→ Common Stock (1,370,168 underlying)Series D Preferred Stock
[F1][F2]→ Common Stock (737,962 underlying)
Footnotes (2)
- [F1]All shares of the preferred stock, par value $0.00001 per share, of the Issuer will automatically be converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock.
- [F2]The securities are directly held by New Enterprise Associates 17, L.P. ("NEA 17") and are indirectly held by NEA Partners 17, L.P. ("NEA Partners 17"), the sole general partner of NEA 17, NEA 17 GP, LLC ("NEA 17 GP"), the sole general partner of NEA Partners 17, and the individual managers of NEA 17 GP (NEA Partners 17, NEA 17 GP and the individual managers of NEA 17 GP (collectively, the "Managers") together, the "Indirect Reporting Persons"). The Mangers are Forest Baskett, Ali Behbahani, Carmen Chang, Anthony Florence, Jr., Mohamad Makhzoumi, Edward Mathers, Scott Sandell, Paul Walker and Rick Yang. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Indirect Reporting Persons have no pecuniary interest.
Signature
/s/ Zachary Bambach, attorney-in-fact|2026-02-05